CAJ | 학술논문

目的：本文就不同雾化吸入方案治疗小儿支气管哮喘的临床效果进行了浅显的研究和探讨。方法：选择我院自2012年12月至2013 年12月期间收治的小儿支气管哮喘患者72例，将其平均分为 A 组 B 组 C 组，三组患者各24例，A 组行沙丁胺醇气雾剂治疗，B 组行沙丁胺醇气雾剂联合丙酸氟替卡松治疗，C 组行沙丁胺醇气雾剂联合布地奈德悬液治疗。对三组患者的治疗效果及不良反应发生率进行观察和统计。结果：三组患者治疗效果之间的差异显著，B、C 组患者的治疗效果明显优于 A组患者的治疗效果，B 组和 C 组治疗效果之间的差异不显著（P>0.05）；三组患者不良反应发生率之间的差异显著，B、C 组患者的不良反应发生率明显低于 A 组患者，B 组和 C 组治疗不良反应发生率之间的差异不显著（P>0.05）。结论：多种药物联合治疗小儿支气管哮喘的效果显著，有效提高了治疗的成功率，值得推广。
목적：본문취불동무화흡입방안치료소인지기관효천적림상효과진행료천현적연구화탐토。방법：선택아원자2012년12월지2013 년12월기간수치적소인지기관효천환자72례，장기평균분위 A 조 B 조 C 조，삼조환자각24례，A 조행사정알순기무제치료，B 조행사정알순기무제연합병산불체잡송치료，C 조행사정알순기무제연합포지내덕현액치료。대삼조환자적치료효과급불량반응발생솔진행관찰화통계。결과：삼조환자치료효과지간적차이현저，B、C 조환자적치료효과명현우우 A조환자적치료효과，B 조화 C 조치료효과지간적차이불현저（P>0.05）；삼조환자불량반응발생솔지간적차이현저，B、C 조환자적불량반응발생솔명현저우 A 조환자，B 조화 C 조치료불량반응발생솔지간적차이불현저（P>0.05）。결론：다충약물연합치료소인지기관효천적효과현저，유효제고료치료적성공솔，치득추엄。
abstract:objective: in this paper, the different schemes atomization inhalation in the treatment of infantile bronchial asthma effect has carried on the shallow study and discussion. Methods: our hospital from December 2012 to December 2013, admitted during the period of 72 cases of infantile bronchial asthma patients, its average can be divided into group A group B, group C all the 24 patients with three groups, group A line of salbutamol aerosol therapy, group B line of salbutamol aerosol with fluticasone propionate therapy, group C line salbutamol aerosol joint budesonide suspension treatment. The treatment effects of three groups of patients and the inci-dence of adverse reactions were observed and statistics. Results: the significant difference between three groups of patients with thera-peutic effect, therapeutic effect in patients with B and C group was obviously better than the therapeutic effect of patients of group A, group B and group C treatment effect between the difference was not significant (P > 0.05); Three groups of patients with significant difference between the incidence of adverse reactions, the incidence of adverse reactions in patients with B and C group was obviously lower than that of group A, B and C group no significant difference in treatment between the incidence of adverse reactions (P > 0.05). Conclusion: the multi-drug therapy of infantile bronchial asthma effect is remarkable, effectively improves the success rate of treatment, is worth promoting.